Our results demonstrate that combinatorial GalNAc–siTACC3/PD-1 mAb treatment outperforms monotherapeutic efficacy through two mechanisms: enhanced tumor growth suppression and microenvironmental reprogramming, which converts immunologically “cold” tumors to “hot” phenotypes. This evidence concerns the gene PDCD1 and neoplasm.